New CEO at Zentek: Can Mohammed Jiwan turn ZenGUARD into a commercial success?

Why is Zentek’s leadership change a turning point for its graphene monetization strategy?

Zentek Ltd. (NASDAQ: ZTEK, TSXV: ZEN) has appointed Mohammed Jiwan as Chief Executive Officer and director, effective December 1, 2025, marking what many observers view as a strategic inflection point. The move comes amid heightened investor scrutiny over Zentek’s prolonged research and development focus and limited progress toward commercial revenue generation, despite a promising portfolio in advanced nanomaterials and antimicrobial coatings.

Based in Ontario, Zentek has developed a proprietary technology known as ZenGUARD, a graphene oxide-based coating with applications in filtration, personal protective equipment, and air purification. However, the firm has struggled to translate its innovations into recurring revenue, with its most recent annual filings showing revenues under US$1 million and net losses exceeding US$7 million. This persistent gap between technological promise and commercial traction has weighed heavily on investor sentiment.

The appointment of Mohammed Jiwan, an executive with more than 20 years of experience in operations and capital markets across technology, life sciences, and innovation-focused firms, is intended to signal a reset. According to Zentek’s board, Jiwan’s arrival is part of a broader repositioning that will emphasize commercial execution, capital efficiency, and shareholder value creation.

Zentek’s share price has declined more than 50 percent in the six months leading up to the announcement, underperforming both sector peers and the broader micro-cap technology space. Although trading volumes saw a mild uptick following the announcement, market participants appear to be taking a wait-and-watch approach, awaiting tangible signs of strategy execution.

What does Mohammed Jiwan’s background reveal about Zentek’s new operational priorities?

Mohammed Jiwan brings a blend of operational leadership, entrepreneurial acumen, and capital market experience that may be well suited to Zentek’s next chapter. He has held executive roles in both private and public companies operating in regulated sectors including healthcare, diagnostics, and innovation-driven manufacturing. While Zentek has not disclosed Jiwan’s most recent prior role, the board has emphasized his track record in scaling early-stage technologies and navigating commercialization pathways across multiple jurisdictions.

Zentek Chair John Snisarenko described the appointment as more than a leadership transition. He characterized it as the beginning of a disciplined transformation that aims to reposition the company within the global nanomaterials market. According to the board’s statement, Jiwan will be responsible for unlocking the value of Zentek’s patent portfolio and product platforms, while instilling a growth-oriented but capital-disciplined culture.

As part of his onboarding, Jiwan has been granted 475,000 stock options priced at US$1.06 per share, in addition to 425,000 restricted share units allocated across officers, directors, and consultants. This equity-based incentive package is designed to align executive performance with long-term shareholder outcomes, especially as Zentek seeks to convert its research investments into revenue-generating commercial assets.

How aligned is Zentek’s current product pipeline with market-ready applications?

Zentek’s core technology assets include ZenGUARD, an antimicrobial coating designed for use in surgical masks, HVAC systems, industrial air filters, and other porous materials. Initially developed during the COVID-19 pandemic, ZenGUARD received Health Canada approval and was incorporated into personal protective equipment at scale. However, post-pandemic demand declined, and Zentek has been actively repositioning the platform toward filtration and industrial use cases.

The company is also exploring applications in corrosion-resistant coatings, pathogen barriers, and material surface enhancement using its graphene oxide formulations. Its Albany Graphite Project, which serves as the firm’s upstream material source, is positioned as a potential differentiator due to its access to high-purity graphite required for functionalized graphene production.

Despite the depth of its intellectual property and growing awareness of graphene’s potential in multiple industries, Zentek’s revenues have not yet reflected scalable product adoption. Analysts tracking the stock have frequently cited the firm’s inability to close commercial agreements or licensing partnerships as a key risk factor. Many believe Zentek must move quickly to showcase product validation through customer pilots, strategic collaborations, or supply agreements in order to justify continued investor confidence.

How is Zentek’s stock performance reflecting investor sentiment around its strategy?

Zentek shares have endured considerable volatility. According to market data, the company’s stock declined approximately 37 percent over the past year, with weekly movement averages around 14 percent. The firm’s market capitalization stands near US$80 million, down significantly from prior highs when investor enthusiasm around nanotechnology and pandemic-driven filtration demand had pushed valuations higher.

Trading activity following the announcement of Jiwan’s appointment showed a modest rebound, though still within the bounds of typical micro-cap fluctuations. No new analyst coverage or revisions were issued immediately, but institutional sentiment remains muted. The shareholder base appears to be composed primarily of retail and early-stage technology investors, with institutional flows showing limited engagement over the last two quarters.

Investor expectations are now centered on a narrow set of deliverables. These include definitive commercial contracts for ZenGUARD, licensing of Zentek’s graphene intellectual property, and updates on production scale-up. Execution on any of these fronts could significantly alter sentiment, but delays or dilution events without progress may deepen existing concerns.

What are analysts expecting from Zentek’s next 6 to 12 months under Jiwan’s leadership?

Analysts and technology sector commentators generally agree that Zentek’s business model hinges on translating its scientific developments into market-facing products and partnerships. Several market observers noted that the firm is now entering a make-or-break phase where commercialization must either accelerate or capital markets support will begin to wane.

Expectations over the next two quarters include updates on product validation pilots in HVAC or industrial coatings, clarity on regulatory pathways for ZenGUARD in international markets, and signals of possible licensing or channel distribution arrangements. Zentek’s Albany Graphite Project may also become a strategic focal point as North American governments and private buyers increase their demand for local critical mineral supply chains.

Commentators believe Mohammed Jiwan’s experience in navigating both regulated markets and public-company scrutiny gives him a solid foundation to steer Zentek through this transition. However, success will depend less on narrative and more on hard deliverables. The first true test will come in the company’s upcoming quarterly filings and investor presentations, where analysts will look for evidence that Jiwan’s operational blueprint is taking shape.

What signals will determine whether Zentek’s transformation is gaining traction?

The clearest signals of momentum will be tied to external validation. This includes partnerships with filtration companies, signed supply contracts for ZenGUARD-integrated products, or licensing deals that monetize the firm’s graphene oxide formulations across verticals. Any public sector endorsements or inclusion in federal procurement programs for air quality or infrastructure could also move the needle.

In parallel, investors will monitor internal metrics such as operating burn, capital allocation toward commercial initiatives, and reduction in non-core R&D. Jiwan may also choose to restructure certain business units or streamline operations to better reflect a commercialization-first model. From a capital markets standpoint, a non-dilutive funding round or joint venture with a strategic partner could ease liquidity concerns and signal institutional confidence in the turnaround story.

Zentek’s next two earnings cycles will serve as barometers of credibility. Analysts expect that if Jiwan is able to communicate a clear commercial roadmap, backed by even modest contract wins or product adoption, institutional participation may increase. Conversely, failure to show progress within the next 9 to 12 months could further depress the stock and limit future financing options.

What are the key takeaways from Zentek’s CEO appointment and commercialization shift?

Zentek Ltd.’s leadership transition represents more than a routine executive change. The appointment of Mohammed Jiwan as Chief Executive Officer reflects a strategic push to finally unlock revenue from its deep research pipeline in nanomaterials and graphene-enabled coatings. The story carries strong investor relevance given the firm’s prolonged losses, high volatility, and underutilized IP base.

Here are the key takeaways:

• Zentek Ltd. has appointed Mohammed Jiwan as CEO and board member, effective December 1, 2025, signaling a strategic pivot toward commercial execution.

• Jiwan brings over 20 years of experience in operations, capital markets, and growth-stage companies, especially in life sciences and technology sectors.

• The appointment follows a more than 50% drop in Zentek’s stock over the last six months, reflecting investor frustration with slow monetization.

• Zentek’s ZenGUARD graphene-based coating technology has regulatory approval but limited commercial scale, with revenue under US$1 million and ongoing losses.

• Jiwan’s onboarding includes 475,000 stock options and 425,000 RSUs to align executive incentives with growth and shareholder value.

• The firm’s Albany Graphite Project remains a strategic asset for its materials pipeline, particularly as North American governments prioritize domestic supply chains.

• Analysts expect updates within two quarters on licensing deals, strategic partnerships, or product sales across HVAC, industrial filtration, or coatings.

• Investor sentiment is cautiously optimistic, with expectations of tangible signs of commercialization before mid-2026.

• Zentek may pursue capital-efficient growth strategies, including non-dilutive funding or revenue-sharing agreements to scale product rollouts.

• Jiwan’s leadership will be evaluated based on the firm’s ability to shift from R&D burn to commercial traction, with investor trust hinging on execution.